Insider · CIK 0001841401

Wahl Bryan

Reports to the SEC for 1 company · IRVINE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001841401

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-19	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−4,231 sh	$67.00	−$283K	63,959
2026-03-18	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−4,125 sh	$68.71	−$283K	68,190
2026-03-17	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−4,084 sh	$69.42	−$284K	72,315
2026-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+24.2K sh	—	—	76,399
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−4,790 sh	—	—	0
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−7,248 sh	—	—	7,249
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−7,176 sh	—	—	14,351
2026-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−5,022 sh	—	—	15,067
2026-03-05	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+27.3K sh	—	—	27,310
2026-03-05	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+17.2K sh	—	—	17,161
2025-03-20	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−3,084 sh	$50.11	−$155K	51,712
2025-03-19	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−3,261 sh	$47.40	−$155K	54,796
2025-03-18	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−3,341 sh	$46.29	−$155K	58,057
2025-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+19.2K sh	—	—	61,398
2025-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−4,790 sh	—	—	4,790
2025-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−7,248 sh	—	—	14,497
2025-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−7,175 sh	—	—	21,527
2025-03-05	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+30.6K sh	—	—	30,628
2025-03-05	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+20.1K sh	—	—	20,089
2024-03-18	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−4,436 sh	$30.60	−$136K	40,951
2024-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+12K sh	—	—	45,387
2024-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−4,790 sh	—	—	9,580
2024-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−7,248 sh	—	—	21,745
2024-03-07	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+42.5K sh	—	—	42,500
2024-03-07	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+28.7K sh	—	—	28,702
2023-11-30	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−8,356 sh	$16.31	−$136K	31,966
2023-11-29	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+23.9K sh	—	—	40,322
2023-11-29	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−23.9K sh	—	—	0
2023-03-23	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−371 sh	$12.15	−$4,507.65	16,402
2023-03-22	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−357 sh	$12.64	−$4,512.48	16,773
2023-03-21	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−350 sh	$12.89	−$4,511.5	17,130
2023-03-20	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−357 sh	$12.61	−$4,501.77	17,480
2023-03-17	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−339 sh	$13.28	−$4,501.92	17,837
2023-03-16	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−337 sh	$13.43	−$4,525.91	18,176
2023-03-15	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+4,790 sh	—	—	18,513
2023-03-15	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−4,790 sh	—	—	14,370
2023-03-08	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+42.8K sh	—	—	42,802
2023-03-08	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+29K sh	—	—	28,993
2022-12-02	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−1,154 sh	$16.90	−$19.5K	13,723
2022-12-01	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−1,164 sh	$16.75	−$19.5K	14,877
2022-11-30	TARSTarsus Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−1,183 sh	$16.50	−$19.5K	16,041
2022-11-29	TARSTarsus Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+10.3K sh	—	—	17,224
2022-11-29	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	General Counsel	MExercise/Conversion	−10.3K sh	—	—	23,920
2022-03-09	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+65.3K sh	—	—	65,312
2022-03-09	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+19.2K sh	—	—	19,160
2022-03-09	TARSTarsus Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	General Counsel	AAward	+34.2K sh	—	—	34,171
2021-02-02	TARSTarsus Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	General Counsel	AAward	+89.4K sh	—	—	89,368

Recent filings

Accepted (ET)
Mar 194
Wahl Bryan0001841401-26-000007
SEC(opens sec.gov)
Mar 174
Wahl Bryan0001841401-26-000005
SEC(opens sec.gov)
Mar 94
Wahl Bryan0001841401-26-000003
SEC(opens sec.gov)
Mar 204
Wahl Bryan0001819790-25-000057
SEC(opens sec.gov)
Mar 184
Wahl Bryan0001819790-25-000044
SEC(opens sec.gov)
Mar 74
Wahl Bryan0001819790-25-000023
SEC(opens sec.gov)
Mar 194
Wahl Bryan0001819790-24-000046
SEC(opens sec.gov)

Companies

Tarsus Pharmaceuticals, Inc.General CounselTARS

Address

C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160

IRVINE, CA, 92618